DOCSLIB.ORG

Pathogenesis of HTN.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathogenesis of HTN.Pdf PHYSIOLOGY IN MEDICINE: A SERIES OF ARTICLES LINKING MEDICINE WITH SCIENCE Physiology in Medicine Dennis A. Ausiello, MD, Editor; Dale J. Benos, PhD, Deputy Editor; Francois Abboud, MD, Associate Editor; Review William Koopman, MD, Associate Editor Annals of Internal Medicine Paul Epstein, MD, Series Editor Pathogenesis of Hypertension Suzanne Oparil, MD; M. Amin Zaman, MD; and David A. Calhoun, MD Clinical Principles Physiologic Principles A clearer understanding of the pathogenesis of hypertension More than 90% of cases of hypertension do not have a clear will probably lead to more highly targeted therapies and to cause. greater reduction in hypertension-related cardiovascular disease morbidity than can be achieved with current Hypertension clusters in families and results from a complex empirical treatment. interaction of genetic and environmental factors. The hypertension-related genes identified to date regulate renal salt and water handling. Major pathophysiologic mechanisms of hypertension include activation of the sympathetic nervous system and renin–angiotensin–aldosterone system. Endothelial dysfunction, increased vascular reactivity, and vascular remodeling may be causes, rather than consequences, of blood pressure elevation; increased vascular stiffness contributes to isolated systolic hypertension in the elderly. ssential hypertension, or hypertension of unknown sity; increased activity of vascular growth factors; alter- Ecause, accounts for more than 90% of cases of hyper- ations in adrenergic receptors that influence heart rate, ino- tension. It tends to cluster in families and represents a tropic properties of the heart, and vascular tone; and collection of genetically based diseases or syndromes with altered cellular ion transport (Figure 1) (2). The novel several resultant inherited biochemical abnormalities (1– concept that structural and functional abnormalities in the 4). The resulting phenotypes can be modulated by various vasculature, including endothelial dysfunction, increased environmental factors, thereby altering the severity of blood oxidative stress, vascular remodeling, and decreased com- pressure elevation and the timing of hypertension onset. pliance, may antedate hypertension and contribute to its Many pathophysiologic factors have been implicated pathogenesis has gained support in recent years. in the genesis of essential hypertension: increased sympathetic Although several factors clearly contribute to the nervous system activity, perhaps related to heightened ex- pathogenesis and maintenance of blood pressure elevation, posure or response to psychosocial stress; overproduction of renal mechanisms probably play a primary role, as hypoth- sodium-retaining hormones and vasoconstrictors; long-term esized by Guyton (5) and reinforced by extensive experi- high sodium intake; inadequate dietary intake of potassium mental and clinical data. As discussed in this paper, other and calcium; increased or inappropriate renin secretion mechanisms amplify (for example, sympathetic nervous with resultant increased production of angiotensin II and system activity and vascular remodeling) or buffer (for ex- aldosterone; deficiencies of vasodilators, such as prostacy- ample, increased natriuretic peptide or kallikrein–kinin ex- clin, nitric oxide (NO), and the natriuretic peptides; alter- pression) the pressor effects of renal salt and water reten- ations in expression of the kallikrein–kinin system that tion. These interacting pathways play major roles in both affect vascular tone and renal salt handling; abnormalities increasing blood pressure and mediating related target or- of resistance vessels, including selective lesions in the renal gan damage. Understanding these complex mechanisms microvasculature; diabetes mellitus; insulin resistance; obe- has important implications for the targeting of antihyper- Ann Intern Med. 2003;139:761-776. For author affiliations, see end of text. © 2003 American College of Physicians 761 Review Pathogenesis of Hypertension Figure 1. Pathophysiologic mechanisms of hypertension. AME ϭ apparent mineralocorticoid excess; CNS ϭ central nervous system; GRA ϭ glucocorticoid-remediable aldosteronism. Reproduced with permis- sion from Crawford and DiMarco (2). tensive therapy to achieve benefits beyond lowering blood factors. Improved techniques of genetic analysis, especially pressure. genome-wide linkage analysis, have enabled a search for genes that contribute to the development of primary hy- GENETICS pertension in the population. Application of these tech- Evidence for genetic influence on blood pressure niques has found statistically significant linkage of blood comes from various sources. Twin studies document pressure to several chromosomal regions, including regions greater concordance of blood pressures in monozygotic linked to familial combined hyperlipidemia (10–13). than dizygotic twins (6), and population studies show These findings suggest that there are many genetic loci, greater similarity in blood pressure within families than each with small effects on blood pressure in the general between families (7). The latter observation is not attrib- population. Overall, however, identifiable single-gene utable to only a shared environment since adoption studies causes of hypertension are uncommon, consistent with a demonstrate greater concordance of blood pressure among multifactorial cause of primary hypertension (14). biological siblings than adoptive siblings living in the same The candidate gene approach typically compares the household (8). Furthermore, single genes can have major prevalence of hypertension or the level of blood pressure effects on blood pressure, accounting for the rare Mende- among individuals of contrasting genotypes at candidate lian forms of high and low blood pressure (3). Although loci in pathways known to be involved in blood pressure identifiable single-gene mutations account for only a small regulation. The most promising findings of such studies percentage of hypertension cases, study of these rare disor- relate to genes of the renin–angiotensin–aldosterone sys- ders may elucidate pathophysiologic mechanisms that pre- tem, such as the M235T variant in the angiotensinogen dispose to more common forms of hypertension and may gene, which has been associated with increased circulat- suggest novel therapeutic approaches (3). Mutations in 10 ing angiotensinogen levels and blood pressure in many genes that cause Mendelian forms of human hypertension distinct populations (15–17), and a common variant in and 9 genes that cause hypotension have been described to the angiotensin-converting enzyme (ACE) gene that has date, as reviewed by Lifton and colleagues (3, 9) (Figure 2). been associated in some studies with blood pressure These mutations affect blood pressure by altering renal salt variation in men (18, 19). However, these variants seem handling, reinforcing the hypothesis of Guyton (5) that the to only modestly affect blood pressure, and other can- development of hypertension depends on genetically deter- didate genes have not shown consistent and reproduc- mined renal dysfunction with resultant salt and water re- ible associations with blood pressure or hypertension in tention (2). larger populations (3); thus, demonstration of common In most cases, hypertension results from a complex genetic causes of hypertension in the general population interaction of genetic, environmental, and demographic remains elusive (16, 20, 21). 762 4 November 2003 Annals of Internal Medicine Volume 139 • Number 9 www.annals.org Pathogenesis of Hypertension Review The best studied monogenic cause of hypertension is particularly in those resistant to conventional pharmaco- the Liddle syndrome, a rare but clinically important disor- logic therapies. der in which constitutive activation of the epithelial so- dium channel predisposes to severe, treatment-resistant hy- pertension (22). Epithelial sodium channel activation has INHERITED CARDIOVASCULAR RISK FACTORS been traced to mutations in the ␤ or ␥ subunits of the Cardiovascular risk factors, including hypertension, channel, resulting in inappropriate sodium retention at the tend to cosegregate more commonly than would be ex- renal collecting duct level. Patients with the Liddle syn- pected by chance. Approximately 40% of persons with es- drome typically present with volume-dependent, low- sential hypertension also have hypercholesterolemia. Ge- renin, and low-aldosterone hypertension. Screenings of netic studies have established a clear association between general hypertensive populations indicate that the Liddle hypertension and dyslipidemia (25). Hypertension and syndrome is rare and does not contribute substantially to type 2 diabetes mellitus also tend to coexist. Hypertension the development of hypertension in the general population is approximately twice as common in persons with diabetes (23). In selected groups, however, evidence suggests that as in persons without diabetes, and the association is even epithelial sodium channel activation might be a more com- stronger in African Americans and Mexican Americans mon cause of hypertension. Epithelial sodium channel ac- (26). The leading cause of death in patients with type 2 tivation, as evidenced by increased sodium conductance in diabetes is coronary heart disease, and diabetes increases peripheral lymphocytes, has been noted in 11 of 44 (25%) the risk for acute myocardial infarction as much as a pre- patients with resistant hypertension (blood pressure uncon-
Load more

Recommended publications
  • High B1a0d Pressure and Its Treatment in General
    HIGH B1A0D PRESSURE AND ITS TREATMENT IN GENERAL PRACTICE WITH PARTICULAR REFERENCE TO A SERIES OF 100 CASES TREATED BY THE AUTHOR By HAROLD WILSON B01YBR IB.ffh.B. ProQuest Number: 13849841 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13849841 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 -CONTENTS SECTION 1. Introduction. SECTION 2. General Remarks. Definitions of General Interest. Present Views on Etiology. Pathology and Morbid Anatomy. Brief Historical Survey. SECTION 3. The Present Position. Prevalence. Clinical Manifestations. Prognosis. SECTION 4. Prevalence in Bolton. Summary of Cases. Symptomatology and Case Histories Prognosis. Treatment. SECTION 5. Conclusions. Bibliography. SECTION 1. INTRODUCTION. I think it can truthfully be said that the most interest­ ing problems in Medioine are those that are most baffling. Some years ago Ralph M a j o r ^ wrote these words, ”If our knowledge of the etiology of arterial hypertension is shrouded in a oertain haze, our knowledge of an effective therapy in this disease is enveloped in a dense fog.n A study of some of the vast literature on this subject does not greatly clarify the obscurity.
    [Show full text]
  • 441.2.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2018-eular.4790 on 12 June 2018. Downloaded from Scientific Abstracts Thursday, 14 June 2018 441 All GCA TAK p (n 23) (n 13) (n 8) Female, n (%) 19 (82.6) 12 (92.3) 6 (75) ns Age at diagnosis 63 (51–68) 68 (63–73) 43.5 (30.5–57) 0.003 Diagnostic latency (months) 4.5 (2–12) 3 (2–10) 8 (3.5–12) ns ESR at disease onset (mm/h) 49 (38–68) 52.5 (45.5– 42 (40–61.5) ns 59.7) CRP at disease onset (mg/L) 61.8 (13– 89 (32.5–106) 60.5 (9.3–132.5) ns 132.5) Disease duration at PET/MR 27 (18–36) 24 (13–29.5) 36.5 (14.75– ns (months) 129.3) ESR at examination (mm/h) 18 (9–35) 16 (7–31) 20.5 (11–44.5) ns CRP at examination (mg/L) 4.5 (2.55–8.9) 3.9 (3.48–4.72) 4.55 (2.05–10.4) ns Results: 23 LVV patients were included, 56.5% GCA, 34.8% TAK and 8.7% iso- Results: Among 602 patients with TA during this period, 119 (19.8%) were jTA, lated aortitis, all Caucasian, mostly females (82%). We considered 55 PET scans, while 483 were aTA. Female predominance was less striking in jTA (71.4%) than 32/55 in LVV group (from min. 1 to max. 3 scans/patient) mainly during follow-up aTA (79%), p=0.047. Patients with jTA had presented more commonly with fever (29/32 scans), and 23/55 in control group.
    [Show full text]
  • Echocardiography in Pediatric Pulmonary Hypertension
    REVIEW ARTICLE published: 12 November 2014 PEDIATRICS doi: 10.3389/fped.2014.00124 Echocardiography in pediatric pulmonary hypertension Pei-Ni Jone* and D. Dunbar Ivy Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA Edited by: Pulmonary hypertension (PH) can be a rapidly progressive and fatal disease. Although Antonio Francesco Corno, Universiti right heart catheterization remains the gold standard in evaluation of PH, echocardiogra- Sains Malaysia, Malaysia phy remains an important tool in screening, diagnosing, evaluating, and following these Reviewed by: Jeffrey Feinstein, Stanford University, patients. In this article, we will review the important echocardiographic parameters of the USA right heart in evaluating its anatomy, hemodynamic assessment, systolic, and diastolic Cecile Tissot, The University function in children with PH. Children’s Hospital, Switzerland Tilman Humpl, SickKids Hospital, Keywords: pediatric pulmonary hypertension, echocardiography, right heart, right ventricular function Canada *Correspondence: Pei-Ni Jone, Pediatric Cardiology, Children’s Hospital Colorado, University of Colorado School of Medicine, 13123 East 16th Avenue, B100, Aurora, CO 80045, USA e-mail: pei-ni.jone@ childrenscolorado.org INTRODUCTION of the RA area in end-systole is performed to evaluate for RA dila- Pulmonary hypertension (PH) is a progressive disease that carries tion (Figure 1)(3). Indexed RA area to body surface area in adult high morbidity and mortality. Although cardiac catheterization is patients with idiopathic PH has been a predictor of mortality and used to define PH, echocardiography is the most important non- has been shown to be a prognostic marker for follow up of PH invasive tool that is used to detect PH (1).
    [Show full text]
  • Effects of Immediate Versus Delayed Antihypertensive Therapy on Outcome in the Systolic Hypertension in Europe Trial Jan A
    Original article 847 Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial Jan A. Staessena, Lutgarde Thijsa, Robert Fagarda, Hilde Celisa, Willem H. Birkenha¨gerb, Christopher J. Bulpittc, Peter W. de Leeuwd, Astrid E. Fletchere, Franc¸oise Forettef, Gastone Leonettig, Patricia McCormackh, Choudomir Nachevi, Eoin O’Brienh, Jose´ L. Rodicioj, Joseph Rosenfeldk, Cinzia Sartil, Jaakko Tuomilehtol, John Websterm, Yair Yodfatn and Alberto Zanchettig, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Background To assess the impact of immediate versus systolic hypertension. Immediate compared with delayed delayed antihypertensive treatment on the outcome of treatment prevented 17 strokes or 25 major cardiovascular older patients with isolated systolic hypertension, we events per 1000 patients followed up for 6 years. These extended the double-blind placebo-controlled Systolic findings underscore the necessity of early treatment of Hypertension in Europe (Syst-Eur) trial by an open-label isolated systolic hypertension. J Hypertens 22:847–857 & follow-up study lasting 4 years. 2004 Lippincott Williams & Wilkins. Methods The Syst-Eur trial included 4695 randomized Journal of Hypertension 2004, 22:847–857 patients with minimum age of 60 years and an untreated Keywords: calcium-channel blocker, clinical trial, isolated systolic blood pressure of 160–219 mmHg systolic and below hypertension, outcome, myocardial infarction, stroke 95 mmHg diastolic. The double-blind
    [Show full text]
  • Orthostatic Hypotension in a Cohort of Hypertensive Patients Referring to a Hypertension Clinic
    Journal of Human Hypertension (2015) 29, 599–603 © 2015 Macmillan Publishers Limited All rights reserved 0950-9240/15 www.nature.com/jhh ORIGINAL ARTICLE Orthostatic hypotension in a cohort of hypertensive patients referring to a hypertension clinic C Di Stefano, V Milazzo, S Totaro, G Sobrero, A Ravera, A Milan, S Maule and F Veglio The prevalence of orthostatic hypotension (OH) in hypertensive patients ranges from 3 to 26%. Drugs are a common cause of non-neurogenic OH. In the present study, we retrospectively evaluated the medical records of 9242 patients with essential hypertension referred to our Hypertension Unit. We analysed data on supine and standing blood pressure values, age, sex, severity of hypertension and therapeutic associations of drugs, commonly used in the treatment of hypertension. OH was present in 957 patients (10.4%). Drug combinations including α-blockers, centrally acting drugs, non-dihydropyridine calcium-channel blockers and diuretics were associated with OH. These pharmacological associations must be administered with caution, especially in hypertensive patients at high risk of OH (elderly or with severe and uncontrolled hypertension). Angiotensin-receptor blocker (ARB) seems to be not related with OH and may have a potential protective effect on the development of OH. Journal of Human Hypertension (2015) 29, 599–603; doi:10.1038/jhh.2014.130; published online 29 January 2015 INTRODUCTION stabilization, and then at 1 and 3 min after standing. The average of the Orthostatic hypotension (OH) is defined as the reduction in blood last two SBP and DBP values measured in the supine position and the pressure (BP) of at least 20 mmHg systolic and/or 10 mm Hg lowest value during standing were considered.
    [Show full text]
  • Hypertension and the Prothrombotic State
    Journal of Human Hypertension (2000) 14, 687–690 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh REVIEW ARTICLE Hypertension and the prothrombotic state GYH Lip Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK The basic underlying pathophysiological processes related to conventional risk factors, target organ dam- underlying the major complications of hypertension age, complications and long-term prognosis, as well as (that is, heart attacks and strokes) are thrombogenesis different antihypertensive treatments. Further work is and atherogenesis. Indeed, despite the blood vessels needed to examine the mechanisms leading to this being exposed to high pressures in hypertension, the phenomenon, the potential prognostic and treatment complications of hypertension are paradoxically throm- implications, and the possible value of measuring these botic in nature rather than haemorrhagic. The evidence parameters in routine clinical practice. suggests that hypertension appears to confer a Journal of Human Hypertension (2000) 14, 687–690 prothrombotic or hypercoagulable state, which can be Keywords: hypercoagulable; prothrombotic; coagulation; haemorheology; prognosis Introduction Indeed, patients with hypertension are well-recog- nised to demonstrate abnormalities of each of these Hypertension is well-recognised to be an important 1 components of Virchow’s triad, leading to a contributor to heart attacks and stroke. Further- prothrombotic or hypercoagulable state.4 Further- more, effective antihypertensive therapy reduces more, the processes of thrombogenesis and athero- strokes by 30–40%, and coronary artery disease by 2 genesis are intimately related, and many of the basic approximately 25%. Nevertheless the basic under- concepts thrombogenesis can be applied to athero- lying pathophysiological processes underlying both genesis.
    [Show full text]
  • Major Clinical Considerations for Secondary Hypertension And
    & Experim l e ca n i t in a l l C Journal of Clinical and Experimental C f a o r d l i a o Thevenard et al., J Clin Exp Cardiolog 2018, 9:11 n l o r g u y o Cardiology DOI: 10.4172/2155-9880.1000616 J ISSN: 2155-9880 Review Article Open Access Major Clinical Considerations for Secondary Hypertension and Treatment Challenges: Systematic Review Gabriela Thevenard1, Nathalia Bordin Dal-Prá1 and Idiberto José Zotarelli Filho2* 1Santa Casa de Misericordia Hospital, São Paulo, Brazil 2Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil *Corresponding author: Idiberto José Zotarelli Filho, Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil, Tel: +5517981666537; E-mail: [email protected] Received date: October 30, 2018; Accepted date: November 23, 2018; Published date: November 30, 2018 Copyright: ©2018 Thevenard G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: In this context, secondary arterial hypertension (SH) is defined as an increase in systemic arterial pressure (SAP) due to an identifiable cause. Only 5 to 10% of patients suffering from hypertension have a secondary form, while the vast majorities have essential hypertension. Objective: This study aimed to describe, through a systematic review, the main considerations on secondary hypertension, presenting its clinical data and main causes, as well as presenting the types of treatments according to the literary results.
    [Show full text]
  • How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT in FPM’S ICD-10 SERIES EXPLAINS the GUIDELINES for CODING HYPERTENSION
    How to Document and Code for Hypertensive Diseases in ICD-10 THIS INSTALLMENT IN FPM’S ICD-10 SERIES EXPLAINS THE GUIDELINES FOR CODING HYPERTENSION. Kenneth D. Beckman, MD, MBA, CPE, CPC ecause ICD-10 can be a distressing topic, let’s start or kidney disease. That code is I10, Essential (primary) with some good news: Hypertension has a limited hypertension. number of ICD-10 codes – only nine codes for pri- As in ICD-9, this code includes “high blood pressure” mary hypertension and five codes for secondary but does not include elevated blood pressure without a B hypertension. This makes the task of coding hypertension diagnosis of hypertension (that would be ICD-10 code relatively simple – well, at least compared to some of the R03.0). If a patient has progressed from elevated blood other ICD-10 complexities. pressure to a formal diagnosis of hypertension, a good Another positive change in ICD-10 is that the new documentation practice would be to include the reason for code set drops the previous reference to benign and progressing the formal diagnosis. Similarly, a single mildly malignant hypertension. As physicians, we are well aware elevated blood pressure reading should be coded with the that hypertension is never truly “benign,” and the removal R03.0 until the formal diagnosis is established. of this antiquated term is a welcome improvement in the Although various sources define hypertension slightly lexicon of diseases. differently, the provider should document elevated systolic But, of course, nothing is easy in ICD-10, and there are pressure above 140 or diastolic pressure above 90 with at several things you need to be aware of before we dig into least two readings on separate office visits.
    [Show full text]
  • The Clinical Significance of Systolic Hypertension
    AJH 1998;11:182S–185S The Clinical Significance of Systolic Hypertension William C. Cushman Downloaded from https://academic.oup.com/ajh/article/11/S8/182S/151642 by guest on 28 September 2021 Large-scale epidemiologic studies and clinical trials Blood Pressure (JNC VI) recommends drug therapy have contributed to an increased recognition of the for all patients with stage 1 (140 to 159 mm Hg) or importance of systolic hypertension. Data from stage 2–3 (> 160 mm Hg) systolic hypertension, landmark epidemiologic studies such as the whether it occurs in isolation or in conjunction Multiple Risk Factor Intervention Trial screenee with diastolic hypertension. The sixth JNC report follow-up and the Framingham Heart Study have identified diuretics as the initial therapy of choice, demonstrated that elevated systolic blood pressure with a long-acting dihydropyridine calcium dramatically increases the risk of cardiovascular channel blocker as an alternative if diuretics are events. Of particular concern is the extremely high ineffective or not well tolerated. More research is risk associated with isolated systolic hypertension needed to evaluate other classes of drugs in this (ISH), which is much more common in the elderly setting. Regardless of the choice of therapy, than in young adults. Clinical trials have identified patients should be encouraged to adopt lifestyle significant risk reductions after treatment with modifications such as weight loss, exercise, sodium diuretics or the dihydropyridine calcium antagonist restriction, and reduced alcohol consumption. nitrendipine in older individuals with ISH. Beta Am J Hypertens 1998;11:182S–185S blockers have not been associated with such benefits. The recently released sixth report of the Joint National Committee on Prevention, KEY WORDS: Cardiovascular risk, systolic Detection, Evaluation, and Treatment of High hypertension.
    [Show full text]
  • The Burden of Pulmonary Hypertension in Resource-Limited Settings Suman Gidwani*, Ajith Nairy Durham, NC, USA; and New York, NY, USA
    j STATE-OF-THE-ART REVIEW gREVIEW The Burden of Pulmonary Hypertension in Resource-Limited Settings Suman Gidwani*, Ajith Nairy Durham, NC, USA; and New York, NY, USA ABSTRACT Pulmonary vascular disease (PVD) is a significant global health problem and accounts for a substantial portion of cardiovascular disease in the developing world. Although there have been considerable advances in therapeutics for pulmonary arterial hypertension, over 97% of the disease burden lies within the developing world where there is limited access to health care and pharmaceuticals. The causes of pulmonary arterial hypertension differ between industrialized and developing nations. Infectious diseases—including schistosomiasis human immunodeficiency virus, and rheumatic fever—are common causes of PVD, as are hemoglobinopathies, and untreated congenital heart disease. High altitude and exposure to household air pollutants also contribute to a significant portion of PVD cases. Although diagnosis of pulmonary arterial hypertension requires the use of imaging and invasive hemodynamics, access to equipment may be limited. PVD therapies may be prohibitively expensive and limited to a select few. Prevention is therefore important in limiting the global PVD burden. Cardiovascular disease accounts for roughly 30% of 2); PH secondary to pulmonary disease (group 3); chronic deaths worldwide and is the leading cause of death globally thromboembolic PH (group 4); and PH from multifactorial [1]. Pulmonary vascular disease (PVD) accounts for a sub- etiologies (group 5) [5] (Table 1). PAH represents a subset stantial burden of cardiovascular disease in resource-limited of PVD that is characterized by pre-capillary PVD. The settings. PVD broadly refers to any disorder that may affect hemodynamic definition of PAH is a mean PA pressure the pulmonary blood circulation.
    [Show full text]
  • Hypertensive Emergencies Are Associated with Elevated Markers of Inflammation, Coagulation, Platelet Activation and fibrinolysis
    Journal of Human Hypertension (2013) 27, 368–373 & 2013 Macmillan Publishers Limited All rights reserved 0950-9240/13 www.nature.com/jhh ORIGINAL ARTICLE Hypertensive emergencies are associated with elevated markers of inflammation, coagulation, platelet activation and fibrinolysis U Derhaschnig1,2, C Testori2, E Riedmueller2, S Aschauer1, M Wolzt1 and B Jilma1 Data from in vitro and animal experiments suggest that progressive endothelial damage with subsequent activation of coagulation and inflammation have a key role in hypertensive crisis. However, clinical investigations are scarce. We hypothesized that hypertensive emergencies are associated with enhanced inflammation, endothelial- and coagulation activation. Thus, we enrolled 60 patients admitted to an emergency department in a prospective, cross-sectional study. We compared markers of coagulation, fibrinolysis (prothrombin fragment F1 þ 2, plasmin–antiplasmin complexes, plasmin-activator inhibitor, tissue plasminogen activator), platelet- and endothelial activation and inflammation (P-selectin, C-reactive protein, leukocyte counts, fibrinogen, soluble vascular adhesion molecule-1, intercellular adhesion molecule-1, myeloperoxidase and asymmetric dimethylarginine) between hypertensive emergencies, urgencies and normotensive patients. In hypertensive emergencies, markers of inflammation and endothelial activation were significantly higher as compared with urgencies and controls (Po0.05). Likewise, plasmin–antiplasmin complexes were 75% higher in emergencies as compared with urgencies (Po0.001), as were tissue plasminogen-activator levels (B30%; Po0.05) and sP-selectin (B40%; Po0.05). In contrast, similar levels of all parameters were found between urgencies and controls. We consistently observed elevated markers of thrombogenesis, fibrinolysis and inflammation in hypertensive emergencies as compared with urgencies. Further studies will be needed to clarify if these alterations are cause or consequence of target organ damage.
    [Show full text]
  • Quality ID #236 (NQF 0018): Controlling High Blood Pressure
    Quality ID #236 (NQF 0018): Controlling High Blood Pressure – National Quality Strategy Domain: Effective Clinical Care – Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Intermediate Outcome – High Priority DESCRIPTION: Percentage of patients 18 - 85 years of age who had a diagnosis of hypertension and whose blood pressure was adequately controlled (< 140/90 mmHg) during the measurement period INSTRUCTIONS: This measure is to be submitted a minimum of once per performance period for patients with hypertension seen during the performance period. The performance period for this measure is 12 months. The most recent quality code submitted will be used for performance calculation. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. NOTE: In reference to the numerator element, only blood pressure readings performed by a clinician in the provider office are acceptable for numerator compliance with this measure. Do not include blood pressure readings that meet the following criteria: • Blood pressure readings from the patient's home (including readings directly from monitoring devices). • Taken on the same day as a diagnostic test or diagnostic or therapeutic procedure that requires a change in diet or change in medication on or one day before the day of the test or procedure, with the exception of fasting blood tests. If no blood pressure is recorded during the measurement period, the patient’s blood pressure is assumed “not controlled”. Measure Submission Type: Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries.
    [Show full text]